Phase 3 Alopecia Areata Trial, Recruiting NCT07146022 Sponsor: Veradermics, Inc. Condition: Alopecia Areata
Back to Alopecia Areata

Phase 3 Alopecia Areata Trial, Recruiting

NCT07146022
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman between 18 and 65 years old
  • You have been diagnosed by a doctor with mild to moderate androgenetic alopecia (a common type of hair thinning or hair loss)
  • You are in good overall health, with kidneys and liver that are working well
  • You are willing to keep your hair at least ¼ inch long throughout the study, and keep the same hairstyle, hair length, and hair color the whole time
  • You are willing to use the same hair care products and routine consistently throughout the study
  • You are able to take the study medication as instructed and can read, understand, and fill out questionnaires written in English
  • You are able to swallow the study medication whole (as a pill or tablet)
  • You agree to have a very small reference dot tattooed on your scalp to help track the same area over time
  • You agree to have that area of your scalp photographed at your study visits

Who may not be able to join:

  • You have uncontrolled high blood pressure, or you experience dizziness or faintness when standing up (orthostatic hypotension)
  • You have a history of, or currently have, certain heart or thyroid conditions (confirm with trial site for specifics)
  • You have hair loss caused by something other than androgenetic alopecia, either now or in the past
  • You have recently made significant changes to your diet or weight, or you are currently taking GLP-1 medications (such as those used for weight loss or diabetes, like Ozempic or Wegovy)
  • You were diagnosed with COVID-19 within the 16 weeks before your first study visit
  • You have had radiation treatment to your scalp at any point in the past
  • You have used hormone replacement therapy or medications that affect hormones within the last 6 months
  • You have taken oral medications for hair growth, including systemic retinoids (a type of vitamin A medication), within the last 6 months
  • You have taken certain blood pressure medications called calcium channel blockers or beta blockers within the last 12 weeks
  • You have taken certain medications including cimetidine, ketoconazole, diazoxide, or steroid medications (by mouth, injection into muscle, joint, or skin) within the last 12 weeks
  • You have had any scalp procedures in the last 6 months, such as surgery, laser treatments, microneedling, injections, or platelet rich plasma therapy
  • You have used any topical (applied to the scalp) hair growth treatments within the last 12 weeks
  • You are using any other medication — either applied to the skin or taken by mouth — that the study doctor believes could affect the study results
  • You have any other health condition that, in the study doctor's opinion, would interfere with the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Reid Waldman, M.D., Veradermics, Inc.

Phone: 858-571-1800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Veradermics, Inc.
Registry
ClinicalTrials.gov
Start date
25 July 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes in non-vellus Target Area Hair Counts (TAHC); Subjects Evaluation of Treatment Benefit

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov